<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758277</url>
  </required_header>
  <id_info>
    <org_study_id>Kep-F10.2.01</org_study_id>
    <nct_id>NCT00758277</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients</brief_title>
  <acronym>Keppra-2</acronym>
  <official_title>Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized double blind controlled trial in prevention of relapse in recently
      detoxified alcohol dependent patients with levetiracetam and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Out-patients with alcohol dependence recently detoxified Primary goal size is the duration of
      the Abstinenz up to the heavy relapse.

      Secondary objective size are:

        -  Frequency of Lapses

        -  Time up to the first alcohol drinking

        -  cumulative times of do not drink

        -  Craving

        -  Alcohol drinking quantity

        -  Sleep quality

        -  Tolerability/Bearableness of the study medication

        -  Security

        -  Drop Out rate

        -  Side effects

        -  Changes with the neuropsychological testing HAM-A, HAM-D, SF12, PSQI, VASC, OCDS, TLFB,
           SCL-90.

        -  Quality of life
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison alcohol free &quot;surviving &quot;(heavy alcohol relapse) between experimental therapy (Keppra®) and a group of placebos</measure>
    <time_frame>During and after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 Time up to first drinking</measure>
    <time_frame>During treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 cumulative Time of do not drinking over the study duration</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 Frequency of Lapses</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of the study medication</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop Out rate</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes with the neuropsychological testing, HAM-A, HAM-D, SF12, VASC, OCDS, TLFB, SCL-90</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Alcoholic Relapse</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levetiracetam (Keppra)</intervention_name>
    <description>levetiracetam daily application 1500-2000 mg</description>
    <arm_group_label>Levetiracetam</arm_group_label>
    <other_name>KEPPRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar Pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 and not older than 70 years

          -  Good knowledge of the German language

          -  The criteria of an alcohol dependence after DSM IV and ICD 10 fulfill

          -  To the recruiting time alkoholabstinently living, i.e. after successful alcohol
             decontamination, the patients must have understood the meaning and consequence of the
             study and have delivered before beginning of study your written agreement to the
             participation.

          -  Negative drug screening regarding Benzodiazepines and Opiates.

          -  With Females either o at least 1 year Menopause or after Sterilization or
             contraceptive pill, mini pill, three-monthly syringe, Implanton, Vaginalring, hormone
             plaster, hormone spiral at least 1 month before study inclusion or use of the double
             barrier method with Spermiziddiaphragma plus condom use or renouncement of sexual
             intercourse during the entire study duration and resolution a pregnancy to avoid with
             negative β-HCG-test

        Exclusion Criteria:

          -  Alcohol withdrawal syndrome beginning or existing

          -  Simultaneous one ambulatory or stationary curing therapy, not however participation in
             groups of self-helps

          -  Specific ones behavior or deep-psychological single therapy or manual-led group
             therapies parallel to the clinical study

          -  Any further substance dependence except nicotine and/or Caffeine dependence A abuse
             according to the criteria of DSM-IV and/or ICD-10 is not considered as exclusion
             reason.

          -  Idiopathic epilepsy, not however admitted alcohol withdrawal convulsions

          -  Anamnesis of heavy cerebral traumas or other heavy neurological illnesses, not however
             alcohol-associated neurological disturbances, e.g. Polyneuropathie

          -  current CO-medication by means of medicines, which can affect significantly withdrawal
             symptoms or Craving or promote the Abstinent( Benzodiazepines, Antiepileptics,
             antipsychotics, Clonidin, antidepressives or Naltrexon (or substances with comparable
             effect mechanism) or Acamprosat, Disulfiram, or further substances, which can affect
             glutamaterge, dopaminerge, cholinergic, serotonerge or opiode system the GABAerge,

          -  Contraindications or heavy side effects in relation to the study medication,
             hypersensitivity opposite Pyrrolidonderivate

          -  Pregnancy or quiet time or insufficient Contraception

          -  Acute severe psychiatric disturbances in need of treatment of the axle I after DSM-IV

          -  Acute Suizidalität, not convincingly arrangementable

          -  Severe internal illnesses, e.g. Pancreatitis, pneumonia, cardiac infarct,
             gastrointestinal bleedings etc.)

          -  Severe kidney damage (starting from dekompensierter retention - stage 3 after that
             national Kidney Foundation) or heavy liver damage (starting from Child A after Child
             Pugh Score with living ore erring trousers) and/or creatinin Clearance of small
             30ml/min

          -  Simultaneous participation or within the last 4 weeks at another clinical study,
             however does not exist an exclusion with previous participation in the decontamination
             study with Keppra ® (Keppra 1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schaefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiarty, Charite Campus Mitte, Berlin, and Department of Psychiatry, Kliniken Essen-Mitte, Essen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <state>Bayern</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfälisches Zentrum Bochum, Psychiatrie, Psychotherapie &amp; Psychosomatik, Klinik der Ruhr-Universität</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Psychotherapie und Suchtmedizin Kliniken Essen - Mitte</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für abhängiges Verhalten und Suchtmedizin, Rheinische Kliniken Essen, Kliniken der Universität Duisburg-Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für abhängiges Verhalten und Suchtmedizin, Rheinische Kliniken, Essen, Kliniken der Universität Duisburg - Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie und Psychotherapie der Martin-Luther-Universität Halle</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PUK Charité im SHK</name>
      <address>
        <city>Berlin</city>
        <zip>10559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes, Wenckebach-Krankenhaus, Klinik für Psychiatrie und Psychotherapie, Gerontopsychiatrie/Psychosomatik</name>
      <address>
        <city>Berlin</city>
        <zip>12099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie und Psychotherapie, Jüdisches Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Krebs M, Leopold K, Richter C, Kienast T, Hinzpeter A, Heinz A, Schaefer M. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol. 2006 Jun;26(3):347-9.</citation>
    <PMID>16702910</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Martin Schaefer, MD</name_title>
    <organization>Charite University, Berlin, Germany</organization>
  </responsible_party>
  <keyword>prevention of alcohol relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

